ARDT

Ardent Health Inc

Add to Watchlist

Advanced Chart

12.690

+0.16(1.277%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

12.725

Open

12.480

VWAP

12.67

Vol

179.77K

Mkt Cap

1.82B

Low

12.410

Amount

2.28M

EV/EBITDA(TTM)

4.85

Total Shares

143.11M

2.78B

EV/OCF(TTM)

9.20

P/S(TTM)

0.29

Ardent Health, Inc., formerly Ardent Health Partners, Inc., is a provider of healthcare in mid-sized urban communities across the United States. Through its subsidiaries, the Company delivers care through a system of 30 acute care hospitals and approximately 280 sites of care with over 1,800 affiliated providers across six states. It provides both general and specialty services, including internal medicine, general surgery, cardiology, oncology, orthopedics, women’s services, neurology, urology, and emergency services, within inpatient and ambulatory care settings. In addition to its 30 acute care hospitals, it operates a network of ambulatory facilities and telehealth services, including primary care and specialty care clinics, ambulatory surgery centers (ASCs), urgent care centers, free-standing emergency departments, and diagnostic imaging centers. It operates a consumer-centric healthcare platform focused on creating relationships with its patients across multiple care settings.

10 Analyst Rating

43.18% Upside

Wall Street analysts forecast ARDT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ARDT is 18.17 USD with a low forecast of 12.00 USD and a high forecast of 23.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

8 Buy

1 Hold

1 Sell

Moderate Buy

43.18% Upside

Current: 12.690

Low

12.00

Averages

18.17

High

23.00

43.18% Upside

Current: 12.690

Low

12.00

Averages

18.17

High

23.00

JPMorgan

Neutral

downgrade

$18 -> $15

2025-08-11

Reason

JPMorgan

Price Target

$18 -> $15

2025-08-11

downgrade

Neutral

Reason

JPMorgan lowered the firm's price target on Ardent Health to $15 from $18 and keeps a Neutral rating on the shares. The firm updated the company's model post the Q2 report.

KeyBanc

Overweight

downgrade

$24 -> $20

2025-08-07

Reason

KeyBanc

Price Target

$24 -> $20

2025-08-07

downgrade

Overweight

Reason

KeyBanc lowered the firm's price target on Ardent Health to $20 from $24 on our lower FY26 estimates, upside potential from Ardent's JV growth strategy, and valuation. The firm keeps an Overweight rating on the shares. KeyBanc notes Q2 results were modestly ahead of expectations on an underlying basis, highlighted by a 1%-2% EBITDA beat that was supported by a continuation of very strong SS growth for IP services.

Leerink

Outperform

NULL

downgrade

$24 -> $23

2025-08-07

Reason

Leerink

Price Target

$24 -> $23

2025-08-07

downgrade

Outperform

NULL

Reason

Leerink lowered the firm's price target on Ardent Health to $23 from $24 and keeps an Outperform rating on the shares. The firm believes Q2 results brought forth many consistent themes anchored to above average demand, solid rate, disciplined cost controls and advancement of the OP agenda. Ardent continues to perform well against targets, carries lots of growth and margin gains and continues to under-earn its potential. Management strikes a confident tone around the development pipeline, has lots of capacity to grow inorganically and has outpaced the sector on admit growth, Leerink adds.

BofA

Neutral -> Underperform

downgrade

$146

2025-07-16

Reason

BofA

Price Target

$146

2025-07-16

downgrade

Neutral -> Underperform

Reason

BofA downgraded Ardent Health to Underperform from Neutral with a $146 price target.

BofA

Joanna Gajuk

Neutral -> Underperform

downgrade

2025-07-16

Reason

BofA

Joanna Gajuk

Price Target

2025-07-16

downgrade

Neutral -> Underperform

Reason

BofA analyst Joanna Gajuk downgraded Ardent Health to Underperform from Neutral with a price target of $14.60, down from $15.50. The firm downgraded four healthcare facility and managed care stocks that it believes are most exposed to the One Big Beautiful Bill. The bill has a board range of negative implications and creates downside risk to growth estimates for the sector, the analyst tells investors in a research note. The subsidy cuts to Medicaid and Affordable Care Act exchanges are not reflected in consensus estimates and for many companies not reflected in stock prices, contends BofA.

Guggenheim

Buy

maintain

$16 -> $18

2025-05-09

Reason

Guggenheim

Price Target

$16 -> $18

2025-05-09

maintain

Buy

Reason

Guggenheim raised the firm's price target on Ardent Health to $18 from $16 and keeps a Buy rating on the shares after Ardent reported Q1 EBITDA slightly above consensus. Ardent shares remain "uniquely attractive" in the context of the current policy backdrop, the analyst tells investors.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Ardent Health Inc (ARDT.N) is 6.74, compared to its 5-year average forward P/E of 8.35. For a more detailed relative valuation and DCF analysis to assess Ardent Health Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Fair

5Y Average PE

8.35

Current PE

6.74

Overvalued PE

10.13

Undervalued PE

6.57

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Undervalued

5Y Average EV/EBITDA

7.69

Current EV/EBITDA

6.26

Overvalued EV/EBITDA

9.00

Undervalued EV/EBITDA

6.38

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Undervalued

5Y Average PS

0.35

Current PS

0.28

Overvalued PS

0.41

Undervalued PS

0.29